Monday, April 15, 2019
Dyadic International (DYAI)
The Importance Behind The Nasdaq Up-Listing.
Dyadic International Inc. is a biotechnology company developing a proprietary expression platform to manufacture of biologic products. The company is employing C1 technology, part of a fungi expression system, to produce variety of modalities of biologic products, including vaccines, oncolytic viruses, monoclonal and bispecific antibodies, as well as biosimilars.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Important Milestone Accomplishment. Dyadic has announced the up-listing of its common stock on The Nasdaq
Capital Market Exchange under stock symbol “DYAI”. The company has
maintained the stock price requirement, for Nasdaq, following its SEC filing on
February 2019. Trading will commence as early as
April 17, 2019 . We believe this
is an important milestone for the company and its current and future investors. - Why is this important? The company has accomplished key
milestones as guided, including the SEC filing and the Nasdaq up-listing. The
stock has gained +112% YTD 2019. We believe the biggest potential benefit from
the up-listing is increased visibility and tran…
Get full report on Channelchek desktop.
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.